Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Source: 
Endpoints
snippet: 

Allergan $AGN rolled out its second wave of positive Phase III data for its oral migraine drug ubrogepant, which nailed its endpoints in the higher dose but failed to elicit much effect in the lower amount.